Australia’s merger control regime is set to undergo its most significant transformation in decades. Starting 1 January 2026, the current voluntary system will be replaced by a mandatory merger notification system. Under the new merger regime, certain acquisitions of assets, including patents, trademarks, designs, copyright (including software) and other intangible assets that meet specified financial thresholds, must be notified to the Australian Competition & Consumer Commission (ACCC) and cannot complete until clearance is granted.[1] While framed as a competition law measure, its impact reaches well beyond traditional mergers and acquisitions. For IP-intensive businesses, transactions that were once considered routine, such as licensing or portfolio transfers, may now attract regulatory scrutiny from the ACCC.
Why this matters for IP owners
IP is no longer a background asset. It has become a major focus of Australia’s merger framework. Transactions that previously proceeded without regulatory hurdles may now require early competition-law assessment, to determine whether they might substantially lessen competition in any market.[2,3] We expect this shift may significantly impact IP-heavy industries like pharmaceuticals, biotechnology, software and consumer brands.
Identifying the thresholds: Is your deal notifiable?
Under the new regime, any acquisition “connected with Australia”, i.e. the target does business here or the IP is used in an Australian business, must be assessed against specific financial triggers.
A transaction is notifiable if it meets any of the following criteria [4]:
- The large merged firm threshold: If the combined Australian revenue of all parties is ≥ A$200m, and either the Australian revenue attributable to the assets is ≥ A$50m, or the global transaction value is ≥ A$250m.
- The very large acquirer threshold: If the acquirer’s Australian revenue is ≥ A$500m, and the Australian revenue attributable to the assets is ≥ A$10m.
- Serial acquisitions: To prevent “creeping” acquisitions, the ACCC will look back three years. Any prior acquisitions of substitutable goods or services are aggregated when assessing the A$50m or A$10m revenue thresholds.
What types of IP transactions may be captured?
- Assignments and certain licences of patents, trademarks, copyright, designs, and plant breeders’ rights
- Transfers of brand portfolios, biotech assets, and data-rich platforms
- Dispute settlements involving IP rights
- Biotech platform acquisitions, compound libraries, data-rich assets
- Joint ventures and research collaborations that generate new IP: Even if current turnover is low, the $250m global transaction value test may apply.
Strategic implications for IP owners, licensors and R&D partners
The transition to a mandatory notification framework necessitates a fundamental shift in how IP transactions are structured and valued. Parties must now look beyond the technical and legal specifications of a patent to consider its broader market impact. The notification process itself will require a mapping of IP to specific products and applications, a task that includes identifying substitute technologies and assessing competitors, customers and potential exclusivity effects.[5]
Furthermore, the new transparency requirements mean that notified deals will be listed on the ACCC’s public register, providing competitors with greater visibility into strategic business activities. The increased scrutiny also carries legal implications, as failure to notify may render a deal void with possible significant penalties. Importantly, any IP rights transferred without the required regulatory clearance may not be enforced until the issue is officially remedied.
To navigate these changes, transaction documents may need to include conditions and timing provisions aligned with regulatory review.
Businesses must also account for the substantial financial commitment involved in the process. A Phase 1 notification costs A$56,800, with Phase 2 reviews attracting additional fees ranging from $475,000 to $1,595,000 depending on the size of transaction. A further A$401,000 may apply for a Phase 3 public benefit application.[1]
Finally, the nature of the IP transfer itself might influence regulatory risk. Assignments that give the assignee complete ownership may attract close ACCC review. Similarly, exclusive licences may raise competition concerns in certain concentrated markets, whereas non-exclusive or field-limited licences typically carry lower risk.
Taken together, these changes underscore the importance of early regulatory awareness when structuring, valuing and executing IP transactions under Australia’s evolving merger control framework.
If you would like to discuss how these changes might affect your strategy, please contact us here.
[1] ACCC. (2025). Merger control regime. Retrieved from https://www.accc.gov.au/business/mergers-and-acquisitions/merger-control-regime
[2] ACCC (2025). Merger assessment guidelines. Retrieved from https://www.accc.gov.au/system/files/merger-control-regime-assessment-guidelines.pdf
[3] ACCC (2025) Merger process guidelines – interim version (Dec 2025). Retrieved from https://www.accc.gov.au/system/files/merger-process-guidelines-interim-version-december-2025_0.pdf
[4] ACCC. (2025). Thresholds and exemptions for acquisition notification. Retrieved from https://www.accc.gov.au/business/mergers-and-acquisitions/merger-control-regime/thresholds-and-exemptions-for-acquisition-notification [5] ACCC (2025). Notifying an acquisition. Retrieved from https://www.accc.gov.au/business/mergers-and-acquisitions/notifying-an-acquisition

